Erratum to: J Transl Med (2016) 14:236 DOI:10.1186/s12967-016-0995-5
Unfortunately, the original version of this article [1] contained errors in the main text and in Tables 2 and 3. Tables 2 and 3 were included incorrectly. The correct Tables 2 and 3 have been updated in the original article and are also included correctly in this erratum.
Table 2.
Baseline characteristics of hemodialysis patients presented as groups according to MBL levels
| Patients | P* < 0.001 | R | P# | |||
|---|---|---|---|---|---|---|
| All (n = 107) | MBL low 319 < ng/mL (n = 26) | MBL high 319 ≥ ng/mL (n = 81) | ||||
| MBL range (ng/mL) | 821 [319–1477] | 98 [33–146] | 1290 [671–1848] | |||
| Demographics | ||||||
| Age, years | 62.5 ± 15.6 | 65.3 ± 12.1 | 61.56 ± 16.6 | 0.3 | −0.26 | 0.007 |
| Male gender, n (%) | 71 (66) | 17 (65) | 54 (67) | 1.0 | ||
| Current diabetes, n (%) | 25 (24) | 9 (35) | 16 (20) | 0.2 | ||
| Hypertension, n (%) | 85 (84) | 22 (88) | 63 (83) | 0.8 | ||
| Cardiovascular history, n (%) | 26 (25) | 9 (35) | 15 (19) | 0.1 | ||
| BMI, kg/m2 | 25.8 ± 4.4 | 27.0 ± 4.5 | 25.4 ± 4.4 | 0.1 | −0.03 | 0.8 |
| Hemodialysis | ||||||
| Dialysis vintage, months | 25.5 [8.5–52.3] | 18.2 [7.0–47.7] | 32.8 [9.1–53.3] | 0.2 | −0.01 | 0.9 |
| Primary renal disease, n (%) | ||||||
| Hypertension | 18 (17) | 4 (15) | 14 (17) | 1.0 | ||
| Diabetes | 14 (13) | 5 (19) | 9 (11) | 0.3 | ||
| ADPKD | 13 (12) | 3 (12) | 10 (12) | 1.0 | ||
| FSGS | 9 (8) | 4 (15) | 5 (6) | 0.2 | ||
| IgA nephropathy | 4 (4) | 0 (0) | 4 (5) | 0.6 | ||
| Chronic pyelonephritis | 3 (3) | 0 (0) | 3 (4) | 1.0 | ||
| Glomerulonephritis | 13 (12) | 2 (8) | 11 (14) | 0.7 | ||
| Other diagnoses | 16 (16) | 6 (23) | 10 (12) | 0.2 | ||
| Unknown | 17 (16) | 2 (8) | 15 (19) | 0.2 | ||
| Ultrafiltration volume, L | 2.55 ± 0.78 | 2.54 ± 0.82 | 2.56 ± 0.78 | 0.9 | −0.01 | 0.9 |
| Ultrafiltration rate, mL/kg/h | 8.56 ± 2.63 | 7.81 ± 2.39 | 8.80 ± 2.67 | 0.1 | 0.04 | 0.7 |
| Systolic blood pressure | ||||||
| Predialysis, mmHg | 140.4 ± 25.1 | 144.7 ± 26.4 | 139.1 ± 24.7 | 0.3 | −0.17 | 0.08 |
| Postdialysis, mmHg | 131.8 ± 25.6 | 136 ± 24.3 | 130.4 ± 26.0 | 0.4 | −0.24 | 0.02 |
| Heart rate | ||||||
| Predialysis, bpm | 73 [63–82] | 71 [62–82] | 74 [64–82] | 0.3 | 0.11 | 0.3 |
| Postdialysis, bpm | 79 [69–87] | 75 [65–86] | 79 [69–88] | 0.4 | 0.13 | 0.2 |
| Kidney transplant, n (%) | 21 (20) | 4 (15) | 17 (21) | 0.8 | ||
| Laboratory measurements | ||||||
| Hematocrit, % | 34.9 ± 3.8 | 34.5 ± 4.1 | 35.0 ± 3.7 | 0.6 | 0.04 | 0.7 |
| HbAlc, mmol/mol | 5.68 ± 0.98 | 5.80 ± 0.97 | 5.63 ± 0.98 | 0.5 | −0.15 | 0.2 |
| Albumin, g/L | 39 [37–42] | 39 [37–42] | 39 [37–42] | 0.9 | 0.01 | 0.9 |
| pH | 7.37 [7.34–7.39] | 7.37 [7.32–7.39] | 7.37 [7.34–7.39] | 0.7 | 0.05 | 0.6 |
| Calcium, mmol/L | 2.31 ± 0.16 | 2.31 ± 0.15 | 2.32 ± 0.16 | 0.9 | 0.03 | 0.7 |
| Phosphate, mmol/L | 1.67 ± 0.53 | 1.82 ± 0.47 | 1.65 ± 0.54 | 0.2 | −0.00 | 0.9 |
| hsCRP, mg/L | 6.7 [2.8–10.9] | 6.1 [1.4–12.0] | 6.7 [3.0–10.9] | 0.7 | 0.10 | 0.3 |
| Medication | ||||||
| Aspirin, n (%) | 57 (54) | 11 (42) | 46 (64) | 0.3 | ||
| Calcium channel blockers, n (%) | 14 (13) | 3 (12) | 11 (14) | 1.0 | ||
| β-Blocker, n (%) | 61 (57) | 18 (69) | 43 (53) | 0.2 | ||
| ACE inhibitor, n (%) | 10 (10) | 3 (12) | 7 (9) | 0.7 | ||
| AT2-receptor antagonists, n (%) | 14 (13) | 2 (8) | 12 (15) | 0.5 | ||
| Statin, n (%) | 20 (19) | 5 (19) | 15 (19) | 1.0 | ||
| Diuretics, n (%) | 8 (8) | 3 (12) | 5 (6) | 0.4 | ||
Italic values used to show which statistical testing was significant (below 0.05)
Data are presented as mean ± SD or median [IQR]
BMI body mass index, ADPKD autosomal dominant polycystic kidney disease, FSGS focal segmental glomerulosclerosis, HDA1c hemoglobin A1c, pH potential hydrogen, hsCRP high sensitive C-relative protein, ACE inhibitor angiotensin-converting-enzyme inhibitor, AT2 receptor antagonists Angiotensin II receptor antagonists
P* indicates P value for the difference in baseline characteristics between the MBL groups, tested by Student’s t test or Mann–Whitney U test for continuous variables and with χ2 test for categorical variables; R indicates Spearman correlation coefficient between MBL levels and the baseline characteristic; P# indicates the corresponding P value
Table 3.
Associations of MBL levels with cardiovascular events and cardiac events in 107 chronic hemodialysis patients
| Low MBL | Log MBL continuous | |||||
|---|---|---|---|---|---|---|
| HR | 95 % CI | P | HR (per SD) | 95 % CI | P | |
| Cardiovascular events | ||||||
| Model 1 | 2.64 | 1.36–5.13 | 0.004 | 0.64 | 0.46–0.90 | 0.01 |
| Model 2 | 2.75 | 1.39–5.44 | 0.004 | 0.61 | 0.43–0.88 | 0.008 |
| Model 3 | 2.94 | 1.45–5.94 | 0.003 | 0.61 | 0.42–0.89 | 0.01 |
| Model 4 | 3.55 | 1.70–7.40 | 0.001 | 0.58 | 0.40–0.84 | 0.004 |
| Model 5 | 3.98 | 1.88–8.42 | <0.001 | 0.56 | 0.38–0.81 | 0.002 |
| Cardiac events | ||||||
| Model 1 | 2.60 | 1.10–6.18 | 0.03 | 0.71 | 0.46–1.10 | 0.1 |
| Model 2 | 2.49 | 1.04–5.96 | 0.04 | 0.73 | 0.46–1.16 | 0.2 |
| Model 3 | 2.65 | 1.08–6.55 | 0.03 | 0.74 | 0.47–1.18 | 0.2 |
| Model 4 | 3.82 | 1.48–9.87 | 0.006 | 0.62 | 0.38–1.01 | 0.06 |
| Model 5 | 3.96 | 1.49–10.54 | 0.006 | 0.59 | 0.35–0.98 | 0.04 |
Model 1: crude
Model 2: adjusted for age and gender
Model 3: adjusted for model 2 plus ultrafiltration volume and dialysis vintage
Model 4: adjusted for model 3 plus cardiovascular history, diabetes and post-HD systolic blood pressure
Model 5: adjusted for model 4 plus hsCRP
Data are presented as hazard ratio (HR) plus 95 % confidence interval (CI) according to the cut-off of MBL and per standard deviation (SD) MBL increase
Italic values used to show which statistical testing was significant (below 0.05)
MBL mannose-binding lectin, HD hemodialysis, hsCRP high sensitive C-reactive protein
Additionally, the following section has been corrected:
However, after adjustment MBL for these confounders levels remained associated with cardiovascular events, indicating a direct and independent effect of MBL on cardiovascular risk.
Should read:
However, after adjustment for these confounders, MBL levels remained associated with cardiovascular events, indicating a direct and independent effect of MBL on cardiovascular risk.
Footnotes
Felix Poppelaars and Mariana Gaya da Costa contributed equally to this work
The online version of the original article can be found under doi:10.1186/s12967-016-0995-5.
Reference
- 1.Poppelaars F, Gaya da Costa M, Berger SP, Assa S, Meter-Arkema AH, Daha MR, van Son WJ, Franssen CFM, Seelen MAJ, et al. Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients. J Transl Med. 2016;14:236. doi: 10.1186/s12967-016-0995-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
